News BeiGene abandons TIGIT antibody after lung cancer flop BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class.
News EU OK sets up first ex-China launches for BeiGene's Tevimbra BeiGene has claimed a second EU approval for PD-1 inhibitor tislelizumab in non-small cell lung cancer (NSCLC), opening the door to the first launches of the drug outside
News Amid sector disruption, biotech must focus on 'fundamentals'... The biotech industry in the US is facing a period of deep uncertainty under the Trump administration, but can ride out the storm, says EY.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
